The TRIPS Agreement significantly influences the availability and affordability of cancer treatments globally. By granting patent protection for pharmaceuticals, TRIPS incentivizes innovation and the development of new cancer therapies. However, it also raises concerns about the cost of these treatments, as patents can limit the production of generic drugs that are often more affordable. This poses a challenge for low- and middle-income countries where cancer treatment may be prohibitively expensive without generic alternatives.
